Evidence map›Paper›PMID 12072499›Full record

ArticleJournal of virology2002

Characterization of human immunodeficiency virus type 1 (HIV-1) Gag- and Gag peptide-specific CD4(+) T-cell clones from an HIV-1-seronegative donor following in vitro immunization.

Sara Venturini, Donald E Mosier, Dennis R Burton, Pascal Poignard

Open access · greenAbstract read
In one paragraph

Article in Journal of virology, 2002. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.8field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 17 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Sara VenturiniDepartment of Immunology, The Scripps Research Institute, La Jolla, California 92037, USA.
Donald E Mosier
Dennis R Burton
Pascal Poignard
Scripps Research Institute · US

Funding

VIRAL EVASION AND HIV ENTRY-BLOCKING STRATEGIESR01AI045357 · NIAID · SCRIPPS RESEARCH INSTITUTE · PI BURTON, DENNIS R. · 2000 to 2004
$1.8M
ANTI-HIV ANTIBODY IMMUNOTHERAPY IN HUPPL-SCID MICER01HL059727 · NHLBI · SCRIPPS RESEARCH INSTITUTE · PI BURTON, DENNIS R. · 1997 to 2001
$1.1M
CELLULAR/LIBRARY APPROACH--ANTIHIV NEUTRALIZING ABSR21AI045376 · NIAID · SCRIPPS RESEARCH INSTITUTE · PI BURTON, DENNIS R. · 1999 to 2000
$264k
NHLBI NIH HHS HL59727NIAID NIH HHS AI45357NIAID NIH HHS AI45376NIAID NIH HHS R01 AI045357
6 · The paper itself

Abstract

Substantial evidence argues that human immunodeficiency virus type 1 (HIV-1)-specific CD4(+) T cells play an important role in the control of HIV-1 replication in infected individuals. Moreover, it is increasingly clear that an HIV vaccine should elicit potent cytotoxic lymphocyte and antibody responses that will likely require an efficient CD4(+) T-cell response. Therefore, understanding and characterizing HIV-specific CD4(+) T-cell responses is an important aim. Here we describe the generation of HIV-1 Gag- and Gag peptide-specific CD4(+) T-cell clones from an HIV-1-seronegative donor by in vitro immunization with HIV-1 Gag peptides. The Gag peptides were able to induce a strong CD4(+) T-cell immune response in peripheral blood mononuclear cells from the HIV-1-seronegative donor. Six Gag peptide-specific CD4(+) T-cell clones were isolated and their epitopes were mapped. The region of p24 between amino acids 201 and 300 of Gag was defined as the immunodominant region of Gag. A new T helper epitope in the p6 protein of Gag was identified. Two clones were shown to recognize Gag peptides and processed Gag protein, while the other four clones reacted only to Gag peptides under the experimental conditions used. Functional analysis of the clones indicated that both Th1 and Th2 types of CD4(+) T cells were obtained. One clone showed direct antigen-specific cytotoxic activity. These clones represent a valuable tool for understanding the cellular immune response to HIV-1, and the study provides new insights into the HIV-1-specific CD4(+) T-cell response and the induction of an anti-Gag and -Gag peptide cellular primary immune response in vitro.

Indexed as

AIDS VaccinesAmino Acid SequenceBlood DonorsCD4-Positive T-LymphocytesClone CellsGene Products, gagHistocompatibility Antigens Class IIHIV-1HIV SeronegativityHumansImmunizationLymphocyte ActivationMolecular Sequence DataPeptidesAIDS VaccinesGene Products, gagHistocompatibility Antigens Class IIPeptides

Identifiers

PMID12072499
PMCPMC136330
OpenAlexW2110350562

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.